These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 8167558)

  • 1. Soluble interleukin-2 receptor levels in cytomegalovirus disease and graft versus host disease after T-lymphocyte depleted bone marrow transplantation for hematological neoplasias.
    Engelhard D; Nagler A; Singer R; Barak V
    Leuk Lymphoma; 1994 Jan; 12(3-4):273-80. PubMed ID: 8167558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation.
    Foley R; Couban S; Walker I; Greene K; Chen CS; Messner H; Gauldie J
    Bone Marrow Transplant; 1998 Apr; 21(8):769-73. PubMed ID: 9603399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease.
    Miyamoto T; Akashi K; Hayashi S; Gondo H; Murakawa M; Tanimoto K; Harada M; Niho Y
    Bone Marrow Transplant; 1996 Feb; 17(2):185-90. PubMed ID: 8640164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease.
    Kobayashi S; Imamura M; Hashino S; Tanaka J; Asaka M
    Leuk Lymphoma; 1997 Dec; 28(1-2):159-69. PubMed ID: 9498715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: a true marker of acute graft-versus-host disease.
    Kami M; Matsumura T; Tanaka Y; Mikami Y; Miyakoshi S; Ueyama J; Morinaga S; Mori S; Machida U; Kanda Y; Chiba S; Sakamaki H; Hirai H; Muto Y
    Leuk Lymphoma; 2000 Aug; 38(5-6):533-40. PubMed ID: 10953974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantations as a marker for GVHD.
    Grimm J; Zeller W; Zander AR
    Bone Marrow Transplant; 1998 Jan; 21(1):29-32. PubMed ID: 9486491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokine levels after HLA-identical bone marrow transplantation.
    Liem LM; van Houwelingen HC; Goulmy E
    Transplantation; 1998 Oct; 66(7):863-71. PubMed ID: 9798695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
    Remberger M; Ringdén O
    Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
    Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
    Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation.
    Toren A; Novick D; Or R; Ackerstein A; Slavin S; Nagler A
    Transplantation; 1996 Jul; 62(1):138-42. PubMed ID: 8693533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation.
    Soiffer RJ; Gonin R; Murray C; Robertson MJ; Cochran K; Chartier S; Cameron C; Daley J; Levine H; Nadler LM
    Blood; 1993 Oct; 82(7):2216-23. PubMed ID: 7691252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning.
    Kaida K; Ikegame K; Ikemoto J; Murata R; Irie R; Yoshihara S; Ishii S; Okada M; Inoue T; Tamaki H; Soma T; Fujimori Y; Kai S; Ogawa H
    Int J Hematol; 2014 Apr; 99(4):463-70. PubMed ID: 24599414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble interferon-gamma receptor and interferon-gamma in patients undergoing allogeneic bone marrow transplantation for hematological malignancies.
    Toren A; Barak V; Novick D; Nagler A
    Cytokines Cell Mol Ther; 1997 Sep; 3(3):153-8. PubMed ID: 9426973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus pneumonia prior to engraftment following T-cell depleted bone marrow transplantation.
    Nagler A; Elishoov H; Kapelushnik Y; Breuer R; Or R; Engelhard D
    Med Oncol; 1994; 11(3-4):127-32. PubMed ID: 7633832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble interleukin-2 receptor index predicts the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
    Nakamura Y; Tanaka Y; Tanaka M; Sugiyama A; Yamamoto K; Tokunaga Y; Yujiri T; Tanizawa Y
    Int J Hematol; 2016 Apr; 103(4):436-43. PubMed ID: 26791380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ganciclovir for the treatment of disseminated CMV disease without pneumonia in allogeneic T-lymphocyte depleted bone marrow transplantation.
    Engelhard D; Naparstek E; Or R; Nagler A; Jacobs J; Shahar MB; Hardan I; Baciu H; Raveh D; Slavin S
    Leuk Lymphoma; 1993 May; 10(1-2):143-6. PubMed ID: 8397030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.